Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 12Prostatic Neoplasms 11Lung Neoplasms 11Oropharyngeal Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Glioma 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Neoplasm Metastasis 6Esophageal Neoplasms 6Mouth Neoplasms 5Carcinoma 5Burkitt Lymphoma 5Astrocytoma 5Sarcoma 4Pancreatic Neoplasms 4Laryngeal Neoplasms 4Gliosarcoma 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Adenocarcinoma of Lung 4Adenocarcinoma Of Esophagus 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Rhabdomyosarcoma, Embryonal 3Rhabdomyosarcoma 3Rectal Neoplasms 3Neoplasms 3

Interventions

Temozolomide 6Specimen Handling 2Radiotherapy 2Magnetic Resonance Spectroscopy 2vocimagene amiretrorepvec 1trametinib 1olutasidenib 1dabrafenib 1abexinostat 1Vorinostat 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Standard of Care 1Spinal Puncture 1Restraint, Physical 1Radiotherapy, Intensity-Modulated 1Radiation 1Protons 1Proton Therapy 1Practice Guidelines as Topic 1Outcome Assessment, Health Care 1Observational Studies as Topic 1Ketoconazole 1Irinotecan 1Heart Rate 1Granulocyte-Macrophage Colony-Stimulating Factor 1Eflornithine 1Diphtheria-Tetanus Vaccine 1DNA 1Craniotomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × Radiation × 90 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡